8.3 Status Epilepticus and Sedation in Brain Injury

Status epilepticus (SE) is a neurological emergency characterized by a failure of the physiological mechanisms that terminate a seizure, or by the initiation of mechanisms that lead to abnormally prolonged seizures. In the neuro-intensive care unit, status epilepticus requires rapid, aggressive, and highly structured pharmacological intervention. Prolonged seizure activity leads to systemic homeostasis collapse and direct excitotoxic neuronal injury due to continuous calcium influx, mitochondrial dysfunction, and activation of apoptotic pathways.

Clinical Definitions and Pathophysiology

Historically, status epilepticus was defined as continuous seizure activity lasting for 30 minutes or longer. However, clinical and animal data demonstrate that irreversible neuronal damage begins much earlier, and seizures lasting longer than 5 minutes are highly unlikely to self-terminate.

Consequently, the Neurocritical Care Society (NCS) and the American Epilepsy Society (AES) utilize an operational definition of status epilepticus based on two time points ($T_1$ and $T_2$):

• $T_1$ (Operational definition for treatment initiation): Continuous clinical and/or electrographic seizure activity lasting $\ge 5$ minutes for convulsive SE (or $\ge 10$ minutes for focal SE, and $\ge 10-15$ minutes for non-convulsive SE), OR two or more discrete seizures without a complete return to baseline consciousness between episodes.
• $T_2$ (Time point of impending long-term neuronal injury): The point at which continuous seizure activity is associated with permanent neurological sequelae (typically $\ge 30$ minutes for convulsive SE and $\ge 60$ minutes for non-convulsive SE).

Classification

1. Convulsive Status Epilepticus (CSE): Characterized by rhythmic, bilateral motor activity (tonic-clonic movements) associated with severely impaired consciousness. CSE is the most common and life-threatening form due to systemic complications like hyperthermia, rhabdomyolysis, severe lactic acidosis, respiratory failure, and cardiac arrhythmias.
2. Non-Convulsive Status Epilepticus (NCSE): Characterized by prolonged electrographic seizure activity on electroencephalography (EEG) presenting with subtle, non-specific clinical signs such as fluctuating confusion, obtundation, subtle facial twitching, or nystagmus. NCSE is highly prevalent in comatose ICU patients and can only be definitively diagnosed via continuous EEG (cEEG) monitoring.

Receptor Trafficking Pathophysiology

As status epilepticus progresses, a critical shift occurs at the synaptic cleft. There is a rapid internalization (downregulation) of inhibitory $\gamma$-aminobutyric acid type A ($\text{GABA}_A$) receptors. Concurrently, there is an upregulation and trafficking of excitatory $\alpha$-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) and N-methyl-D-aspartate (NMDA) receptors to the synaptic membrane.

This molecular shift explains why status epilepticus becomes progressively resistant to benzodiazepines (which require functional $\text{GABA}_A$ receptors) and highlights the therapeutic rationale for utilizing non-GABAergic agents in later stages.

---

Multi-Stage Pharmacotherapy Algorithm

Management of status epilepticus follows a time-delimited, stepwise protocol. Delaying therapy is strongly correlated with treatment failure.

Phase 1: Emergent Initial Therapy (0 to 20 minutes)

The first-line therapy for active status epilepticus consists of rapidly acting benzodiazepines. These agents act as positive allosteric modulators of the $\text{GABA}_A$ receptor, increasing chloride conductance and hyperpolarizing the neuronal membrane.

• Intramuscular Midazolam: Dosed at 10 mg IM (for patients > 40 kg; 5 mg for 13-40 kg). In patients without pre-existing intravenous access, IM midazolam is the drug of choice. Because of its high water solubility, it is rapidly absorbed from muscle tissue, achieving therapeutic levels faster than attempts to establish IV access.
• Intravenous Lorazepam: Dosed at 4 mg IV (may repeat once if seizures continue after 5-10 minutes). Lorazepam is the preferred agent when IV access is already established. It has lower lipid solubility compared to diazepam, meaning it does not redistribute rapidly into adipose tissue. Consequently, it maintains an effective concentration in the central nervous system for 6 to 12 hours.
• Intravenous Diazepam: Dosed at 5 to 10 mg IV (may repeat once). Diazepam is highly lipophilic and crosses the blood-brain barrier within seconds. However, it rapidly redistributes into peripheral fat stores, causing its brain concentration to drop quickly. This results in a short clinical duration of action (15 to 30 minutes) and a high rate of seizure recurrence.
• Monitoring: The primary adverse effect of emergent benzodiazepines is respiratory depression and hypotension. Clinicians must monitor respiratory rate, oxygen saturation, and blood pressure closely. Preparations for advanced airway management must be made, although intubation is often required due to the underlying seizure itself rather than the benzodiazepines.

Phase 2: Urgent Control Therapy (20 to 40 minutes)

If the seizure continues despite an adequate dose of a first-line benzodiazepine, or if the seizure has stopped but long-term control is required, a second-line, non-sedating antiseizure medication (ASM) must be loaded immediately. The Established Status Epilepticus Treatment Trial (ESETT) compared levetiracetam, fosphenytoin, and valproic acid in status epilepticus and found no significant differences in safety or efficacy (approximately 50% success rate for all three).

• Levetiracetam: Dosed at 60 mg/kg IV (maximum dose 4,500 mg) infused over 5 to 10 minutes.
  • Mechanism: Binds to synaptic vesicle protein 2A (SV2A), modulating neurotransmitter release.
  • Safety: Extremely well-tolerated with virtually no hemodynamic or cardiotoxic adverse effects. It does not undergo hepatic metabolism and has no significant drug-drug interactions. Dose adjustments are required in patients with pre-existing renal impairment.
• Fosphenytoin: A water-soluble prodrug of phenytoin, dosed in Phenytoin Equivalents (PE). Dosed at 20 mg PE/kg IV (up to 30 mg PE/kg).
  • Mechanism: Blockade of voltage-gated sodium channels, prolonging the refractory period of the neuron.
  • Administration Limits: Fosphenytoin can be infused faster than phenytoin (up to 150 mg PE/min). However, it still carries a black-box warning for cardiotoxicity. The rate of infusion must not exceed 150 mg PE/min to minimize the risk of severe hypotension and cardiac arrhythmias (such as QT prolongation, AV block, and QRS widening). Continuous ECG and blood pressure monitoring are mandatory during the infusion. It should be avoided in patients with bradycardia or high-degree heart block.
• Valproate Sodium: Dosed at 40 mg/kg IV (maximum dose 3,000 mg) infused at a rate of 3 to 6 mg/kg/min (up to 10 mg/kg/min).
  • Mechanism: Broad-spectrum activity, including blocking sodium channels, enhancing GABA synthesis/inhibiting GABA degradation, and blocking T-type calcium channels.
  • Safety: Generally hemodynamically stable. It is strictly contraindicated in patients with acute hepatic dysfunction, acute pancreatitis, or suspected mitochondrial disorders (e.g., Alpers-Huttenlocher syndrome due to risk of fatal hepatotoxicity). It can also cause hyperammonemia, which can worsen encephalopathy.
• Lacosamide: Dosed at 200 to 400 mg IV infused over 15 minutes.
  • Mechanism: Enhances slow inactivation of voltage-gated sodium channels.
  • Safety: Lacosamide is increasingly used due to its favorable side effect profile and low drug interaction rate. PR interval prolongation can occur, and caution should be exercised in patients with underlying conduction disease (an ECG should ideally be reviewed).

Phase 3: Refractory Status Epilepticus (> 40 minutes)

Refractory Status Epilepticus (RSE) is defined as continuous or recurrent seizure activity that persists despite the administration of at least one first-line benzodiazepine and one second-line non-sedating ASM at adequate doses.

At this stage, patients must be emergently intubated, mechanically ventilated, and admitted to the ICU. Treatment requires continuous infusions of anesthetic agents titrated to a target of electrographic seizure cessation or burst suppression on continuous EEG (cEEG).

• Propofol: Initiated with a loading bolus of 1 to 2 mg/kg IV, followed by a continuous infusion of 2 to 10 mg/kg/hr (30 to 150 mcg/kg/min).
  • Mechanism: Agonist at the $\text{GABA}_A$ receptor and antagonist at the NMDA receptor.
  • Clinical Use: Provides rapid seizure control and has a very short context-sensitive half-life, allowing for rapid clearance.
  • Warning: Prolonged infusions at high doses ($> 4-5\text{ mg/kg/hr}$ or $> 80\text{ mcg/kg/min}$ for $> 48\text{ hours}$) carry a high risk of Propofol-Related Infusion Syndrome (PRIS). PRIS is characterized by severe metabolic acidosis, rhabdomyolysis, hyperkalemia, acute kidney injury, hepatomegaly, and hypertriglyceridemia, leading to refractory bradycardia and asystole.
• Midazolam Continuous Infusion: Initiated with a loading bolus of 0.2 mg/kg IV, followed by a continuous infusion of 0.05 to 2 mg/kg/hr.
  • Clinical Use: Highly effective, but midazolam is lipophilic and accumulates significantly in adipose tissue during prolonged infusions. Its active metabolite (1-hydroxymidazolam) also accumulates in renal impairment, leading to prolonged sedation and delayed emergence.
• Pentobarbital: Initiated with a loading bolus of 5 to 20 mg/kg IV, followed by a maintenance infusion of 1 to 5 mg/kg/hr.
  • Clinical Use: Extremely effective for refractory seizures but causes profound myocardial depression and venodilation. Vasopressor support is universally required to maintain target blood pressure and CPP.
• Ketamine: Initiated with a loading bolus of 1 to 2 mg/kg IV, followed by an infusion of 0.5 to 5 mg/kg/hr.
  • Mechanism: Non-competitive NMDA receptor antagonist.
  • Clinical Use: Because NMDA receptors are upregulated and $\text{GABA}_A$ receptors are internalized in prolonged SE, ketamine represents a highly logical and effective synergist, particularly when GABAergic agents are failing. It is hemodynamically stable and does not cause myocardial depression.

---

Sedation in the Brain-Injured Patient

Sedation in neurocritical care is uniquely challenging. The primary objective is to facilitate mechanical ventilation, manage ICP, and reduce metabolic demand without permanently masking the neurological exam.

Propofol

Propofol is a GABA agonist and the workhorse sedative in the neuro-ICU.

• Benefits: Highly lipid soluble, providing rapid onset. Crucially, it has a very short context-sensitive half-time with short-term use. When the infusion is paused (a "sedation vacation"), patients wake up rapidly, allowing the intensivist to perform a reliable neurological assessment.
• Additional Neuro Effects: Decreases CMRO2 and ICP.
• Propofol-Related Infusion Syndrome (PRIS): A rare but fatal complication associated with high doses (> 4-5 mg/kg/hr) for prolonged periods (> 48 hours). Characterized by severe metabolic acidosis, rhabdomyolysis, hyperkalemia, acute kidney injury, and refractory bradycardia progressing to asystole.

Dexmedetomidine (Precedex)

An alpha-2 adrenergic agonist providing "cooperative sedation" and analgesia.

• Benefits: Does not cause respiratory depression. Patients are easily arousable, which is highly beneficial for neurological examinations.
• Drawbacks: Often lacks the depth of sedation required to manage severe intracranial hypertension. Frequently causes bradycardia and hypotension.

Analgesia-First (Analgo-sedation)

Pain must be addressed before or concurrently with sedation. Fentanyl, a synthetic opioid, is preferred over morphine due to its rapid onset, shorter duration, and lack of histamine release (which could theoretically cause vasodilation and increase ICP).

---

Super-Refractory Status Epilepticus (SRSE) and the Role of cEEG

• Super-Refractory Status Epilepticus (SRSE): Defined as status epilepticus that continues or recurs 24 hours or more after the initiation of continuous anesthetic infusions, including cases where seizures recur during the reduction or withdrawal of anesthetic therapy. Management of SRSE is highly complex and lacks high-level clinical trial evidence. Interventions include:
  • Alternative Pharmacotherapy: Inhaled anesthetics (isoflurane), ketogenic diet (which produces decanoic acid and acetone, acting as direct anticonvulsants), therapeutic hypothermia, immunomodulatory therapies (IVIG, high-dose corticosteroids, plasmapheresis for autoimmune encephalitis), and neurosteroids (allopregnanolone).
  • Surgical Interventions: Emergency resective surgery, vagus nerve stimulation (VNS), or electroconvulsive therapy (ECT).
• The Role of Continuous EEG (cEEG) Monitoring:
  • Once a patient is placed on continuous anesthetic infusions, clinical signs of seizure activity (motor movements) are abolished by the sedative-anesthetic agents or co-administered neuromuscular blockers. However, subclinical electrographic seizure activity may persist in the brain, causing ongoing damage.
  • cEEG monitoring is mandatory in the ICU for all patients in refractory status epilepticus. It is used to guide the titration of anesthetic infusions. The target is typically either complete suppression of all seizure activity or burst suppression (e.g., a burst-suppression ratio of 80% to 90%, or 10 to 15 seconds of suppression between bursts), sustained for 24 to 48 hours before attempting a gradual taper.